Giancarlo Comi, M.D. On Behalf of the MS-LAQ-301 (ALLEGRO) Study Group. Assessment of oral laquinimod in preventing progression of Multiple Sclerosis
|
|
- Elisabeth Conley
- 6 years ago
- Views:
Transcription
1 COMPARISON OF EARLY AND DELAYED ORAL LAQUINIMOD IN PATIENTS WITH RELAPSING- REMITTING MULTIPLE SCLEROSIS: EFFECTS ON DISABILITY PROGRESSION AT 36 MONTHS IN THE ALLEGRO TRIAL Giancarlo Comi, M.D. On Behalf of the MS-LAQ-301 (ALLEGRO) Study Group Assessment of oral laquinimod in preventing progression of Multiple Sclerosis
2 DISCLOSURES G. Comi received consulting fees for advisory boards, consultancy and speaker activities from Novartis, Teva Pharmaceutical Industries, Ltd., Sanofi-Aventis, Merck Serono, and Bayer Schering; and lecture fees from Novartis and Teva Pharmaceutical Industries, Ltd. D. Jeffery has received honoraria and consulting fees from Berlex, Serono, Teva, Glaxo and Pfizer; and financial support for research from Bayer, Serono, Teva, and Pfizer. L. Kappos has received personal compensation from Actelion, Advancell, Allozyne, BaroFold, Bayer Health Care Pharmaceuticals, Bayer Schering Pharma, Bayhill, Biogen Idec, BioMarin, CLC Behring, Elan, Genmab, Genmark, GeNeuro SA, GlaxoSmithKline, and Lilly. X. Montalban has received honoraria for speaking, travel expenses to scientific meetings; is a steering committee member or has participated in advisory boards in clinical trials or has had consulting agreements with Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech, Genzyme, Novartis, Sanofi- Aventis, and Teva Pharmaceuticals. A. Boyko is a member of advisory boards and participant in clinical trials sponsored by Bayer Schering, Merck Serono, Teva, Novartis, Biogen, Nycomed, Genzyme, and other companies. M. Rocca serves as consultant to Bayer Schering Pharma; received speakers bureaus for Biogen Idec, and receives research support from the Italian Ministry of Health. M. Filippi has received personal compensation for activities with Merck-Serono, Genmab, Biogen Idec, Bayer-Schering, and Teva Neuroscience as a consultant, speaker, and advisory board member. He receives research support from Merck-Serono, Biogen Idec, Bayer-Schering, Teva Neuroscience, Fondazione Italiana Sclerosi Multipla and Italian Ministry of Health.
3 LAQUINIMOD SITE OF ACTION Activated T cell Pro-inflammatory Cytokines IL-1β IFN γ Astrocyte Auto-reactive T cell Proinflammatory Cytokines Activated Astrocytes Activated Astrocytes Glial Scar Formation Microglia TNF-α, NO, O2 AXONAL DAMAGE Oligodendrocyte Myelin residue Oligodendrocyte Damage/Apoptosis Degenerative Trigger
4 ALLEGRO PHASE 3 TRIAL The ALLEGRO study was a Phase 3 trial of oral laquinimod 0.6mg in RRMS patients (N=1106), showing: Percent Brain Volume Change (Months 0-24) 23% Reduction % Reduction in the Risk p= PLACEBO LAQUINIMOD 0.6mg Annualized for Disability Progression Relapse Rate p= No signal of immunosuppression No evidence of cardiac events % Transient elevations of liver enzymes, without clinical signs of liver damage/bilirubinemia Safety & Tolerability: 0 Increased incidence of abdominal pain and back pain without needing -1.30% to stop laquinimod PLACEBO LAQUINIMOD 0.6mg % Reduction in Brain Volume Loss p<0.0001
5 ALLEGRO S 36 MONTH OPEN-LABEL EXTENSION OBJECTIVE Compare progression of disability and safety of patients treated with laquinimod for 36 months to patients originally treated with placebo in the double-blind phase and switched to laquinimod treatment in the open-label extension
6 STUDY DESIGN Double-Blind Phase Oral Laquinimod 0.6mg once daily OPEN-LABEL EXTENSION PHASE Matching Oral Placebo once daily Oral Laquinimod 0.6mg once daily Mo Mo 6 Mo 9 Mo 12 Mo 15 Mo 18 Mo 21 Mo 24 Mo 30 Mo 36 EDSS Safety MRI
7 PARTICIPANTS Early Start patients Those randomized to laquinimod during the DB phase and continuing on treatment in the OL extension Delayed Start patients Those randomized to placebo during the DB phase and began laquinimod treatment during the OL extension
8 OUTCOME MEASURES Relapses Patients are instructed to call sites indicating any symptoms suggestive of a relapse lasting for 48 hours or more and confirmed by a physician within 7 days of onset. Disability Safety Progression of disability defined as an increase from baseline EDSS score of 1.0 or more points if baseline EDSS is 0 to 5.0 or 0.5 points if baseline EDSS is 5.5 or higher, sustained for 6 months. Adverse events, laboratory tests including liver enzymes and complete blood counts, physical exams and ECGs were assessed.
9 PATIENT DISPOSITION Randomized (n = 1106) Laquinimod 0.6mg (N = 550) Placebo (N = 556) Completed 24 Months of Double Blind Treatment n = 437 n = 427 Entered Open Label Extension Early Start n = 423 Delayed Start n = 416 Completed 12 Months of Open Label Extension Early Start n = 372 (87%) Delayed Start n = 368 (87%)
10 BASELINE DEMOGRAPHICS OF PATIENTS ENTERING OL PHASE MS LAQ 301 Early Start (n = 423) Delayed Start (n = 416) Age mean ± SD 39.1 ± ± 9.1 Female n (%) 298 (70.4%) 271 (65.1%) Time since diagnosis (years) mean ± SD 5.4 ± ± 4.8 Time since 1st symptom (years) mean ± SD 9.0 ± ± 6.4 Baseline converted EDSS mean ± SD 2.6 ± ± Relapse in 1 yr prior to screening (%) 394 (93.1%) 391 (94.0%) Number of relapses mean ± SD 1.2 ± ± 0.7 Number of GdE-T1 lesions mean ± SD 1.8 ± ± 4.3 % Patients with GdE-T1 lesions 1 at baseline 40.0% 46.6%* Volume of T2 lesions (cm 3 ) mean ± SD 10.0 ± ± 9.7 * Significantly different
11 REASONS FOR STUDY TERMINATION Early Start (n = 52) Delayed Start (n = 53) 4% 4% 4% 2% 4% 6% 2% 4% 8% 21% 50% Patient withdrew consent Adverse Event 23% 55% 15% Physician withdrew consent Protocol violation Pregnancy Lost to Followup Death
12 RESULTS: ANNUALIZED RELAPSE RATE 1.4 Annualized Relapse Rate Early Start (n=547) Delayed Start (n=556) Early Start patients have a lower cumulative 3 year relapse rate compared to Delayed Start patients (0.274 vs 0.340, -19.4% P = ). Delayed Start Laquinimod 0.6 mg Week on Study
13 YEARLY RELAPSE RATES Early Start Delayed Start RR = p = <0.01 RR = p = RR = p = <0.01 RR = p = Year 1 DB Year 2 DB Year 1 OL 0 Year 1 DB Year 2 DB Year 1 OL
14 PROPORTION OF PATIENTS WITH 6 MONTH CONFIRMED DISABILITY AT 36 MONTHS MS-LAQ-301 All patients Patients on laquinimod during DB and Early Start in OL (n = 550) Patients on placebo during DB and Delayed Start in OL (n = 556) N % N % Progression Free Progressed
15 CONFIRMED 6 MONTH DISABILITY PROGRESSION FOR ALL PATIENTS IN ALLEGRO DB AND OL PHASES % of Patients with Confirmed Progression 30% 25% 20% 15% 10% 5% 0% Delayed Start Early Start Delayed Start Laquinimod 0.6 mg Delayed Start n= Early Start n= Time to Progression (Days) HR = P =
16 ADVERSE EVENTS Percent (%) of Patients Reporting the AE Laquinimod 0.6 mg Placebo DB Phase Early Start Delayed Start OL Phase *Adverse events reported by 5% of patients that occurred with 1% higher incidence with laquinimod in the pooled data set compared with placebo. ALT = alanine aminotransferase; UTI = urinary tract infection
17 LIVER ENZYME ELEVATIONS EARLY START (no. of patients/total no. of patients (%) DB Phase OL Phase ALT Increase only in OL Phase >1 and 3 ULN 151/504 (30%) 43/387 (11.1%) 12/43 (27.9%) >3 and 5 ULN 18/504 (3.6%) 2/387 (0.5%) 1/2 (50.0%) >5 and 8 ULN 3/504 (0.6%) 4/387 (1.0%) 2/4 (50.0%) >8 ULN 3/504 (0.6%) 0 0 DELAYED START DB Phase OL Phase ALT Increase only in OL Phase >1 and 3 ULN 91/515 (17.7%) 104/388 (26.8%) 71/104 (68.2%) >3 and 5 ULN 2/515 (0.4%) 5/388 (1.3%) 3/5 (60%) >5 and 8 ULN 3/515 (0.6%) 0 0 >8 ULN 3/515 (0.6%) 0 0
18 SAEs EARLY START (Laquinimod/Laquinimod) Serious Adverse Events No. Incident (No. and % patient) DB Phase (n = 550) Diarrhoea 2 (2, 0.4%) - Vomiting 3 (1, 0.2%) - Fever 2(2, 0.4%) - Peripheral Edema 2 (2, 0.4%) - OL Phase (n = 423) Appendicitis 5 (5,0.9%) 3 (3, 0.7%) Cellulitis 2 (2, 0.2%) 1 (1, 0.2%) Hypokalemia 4 (2,0.4%) 1 (1, 0.2%) Uterine leiomyoma 2 (2, 0.4%) 1 (1, 0.2%) Headache 2(2, 0.4%) - Abdominal pain 1(1,0.2%) 2 (2, 0.4%) C-reactive protein increase - 3 (3, 0.7%) Back pain 1(1, 0.2%) 1 (1, 0.2%) Chest pain - 1(1, 0.2%)
19 SAEs DELAYED START (Placebo/Laquinimod) Serious Adverse Events No. Incident (No. and % patient) DB Phase (n = 556) OL Phase (n = 416) Diarrhoea - - Vomiting - - Fever - - Peripheral Edema - - Appendicitis 1 (1,0.2%) 2 (2, 0.4%) Cellulitis - - Hypokalemia - - Uterine leiomyoma 1 (1, 0.2%) - Headache - - Abdominal pain 2 (2, 0.4%) 1 (1, 0.2%) C-reactive protein increase - - Back pain - - Chest pain 4 (3, 0.5%) 1 (1, 0.2%) Gastritis 2 (2, 0.4%) - Cholelithiasis 2 (2, 0.4%) - Liver Disorder 2 (2, 0.4%) - Pneumonia 2 (2, 0.4%) - Dyspnea 2(2, 0.4%) -
20 SAE - MALIGNANCIES DB Phase OL Phase Laquinimod Placebo (n = 550) (n = 556) Basal-cell carcinoma 1 (0.2) 1 (0.2) Breast cancer 3 (0.5) 1 (0.2) Lung neoplasm 1 (0.2) 0 Lymphoma 1 (0.2) 0 Esophageal adenocarcinoma 1 (0.2) 0 Ovarian cancer 0 2 (0.4) Prostate cancer 0 1 (0.2) Glioblastoma 1 (0.2) 0 Rectal cancer 0 1 (0.2) Early Start Delayed Start (n = 423) (n = 416) Thyroid cancer 0 1 (0.2) Skin cancer 0 1 (0.2) Breast cancer 1 (0.2) 0 Bone cancer 1 (0.2) 0
21 DEATHS 5 deaths in the ALLEGRO trial DB Phase 1 placebo patient died from complications due to pneumonia 1 placebo patient had a train accident 1 placebo patient committed suicide OL Phase 1 patient had an acute coronary attack 1 patient committed suicide
22 CONCLUSIONS Patients who shifted from placebo to laquinimod in OL phase had a significant reduction in relapse rate Patients on early treatment compared to those on delayed treatment had a significant reduction in risk of disability progression No new safety concerns emerged in the open-label in the early treatment or those exposed to laquinimod beginning in the openlabel phase For patients who were on early treatment, there was a global tendency to decrease the incident of SAEs from the double-blind to the open-label phase. For patients who were exposed for the first time in the open-label phase, the AEs were similar to those seen previously with laquinimod in the double-blind phase.
Patient 1: 31-Year-Old Female. Fingolimod treatment
Cell Counts (10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Lymphocyte Pharmacodynamics and Safety of Use in Patients Previously
More informationLong-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing remitting multiple sclerosis: the CLARITY Extension study
753365TAN0010.1177/1756285617753365Therapeutic Advances in Neurological DisordersG Comi, S CooK research-article2018 Therapeutic Advances in Neurological Disorders Original Research Long-term effects of
More informationThe Effects of Daclizumab High Yield Process (DAC HYP) on Patient Centered Functional Outcomes: Results From the DECIDE Study
2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers May 27 30, 2015 Indianapolis, IN The Effects of Daclizumab High Yield Process () on Patient Centered Functional Outcomes: Results From
More informationEfficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
RESEARCH ARTICLE Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials Vissia Viglietta 1, David Miller 2, Amit Bar-Or 3, J.
More informationMS Trust Comments on the ACD
MS Trust Comments on the ACD Name xxxxxxxxxxx Role other Other role xxxxxxxxxxxxxxxxxx Location England Conflict no Notes Comments on individual sections of the ACD: Section 1 The MS Trust maintains that
More informationMitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA Disclosures Consultant and Speaker Bureau member for Biogen-Idec, Pfizer, TEVA Neuroscience, Bayer, EMD Serrono, Questcor, Novartis,
More informationPer Soelberg Sørensen
Per Soelberg Sørensen Danish Multiple Sclerosis Center Department of Neurology Rigshospitalet, University of Copenhagen Copenhagen, Denmark Declared receipt personal compensation for serving on scientific
More informationAbstract. n engl j med 362;5 nejm.org february 4,
The new england journal of medicine established in 1812 february 4, 2010 vol. 362 no. 5 A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis Ludwig Kappos, M.D., Ernst-Wilhelm
More informationTHC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms
Review Published online: February 23, 2016 THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms Maria Trojano Department of Basic Medical Sciences, Neurosciences
More informationKeywords Fingolimod Multiple sclerosis Safety Tolerability. Introduction
J Neurol (214) 261:267 276 DOI 1.17/s415-13-7115-8 ORIGINAL COMMUNICATION Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a
More informationEvidence from bone marrow transplantation
Evidence from bone marrow transplantation Gianluigi Mancardi Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Ospedale Policlinico San Martino, University
More informationTeriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
507821MSJ20610.1177/1352458513507821Multiple Sclerosis JournalVermersch et al. 2013 Research Paper MULTIPLE SCLEROSIS JOURNAL MSJ versus subcutaneous interferon beta-1a in patients with relapsing multiple
More informationEAN Amsterdam June 23-27, 2017
EAN 2017 Amsterdam June 23-27, 2017 MS Nowadays-new goals Giancarlo Comi Dept. of Neurology & Institute of Experimental Neurology Università Vita Salute S.Raffaele, Milano European Charcot Foundation Disclosure
More informationSwitching from natalizumab to fingolimod: an observational study
Acta Neurol Scand 2013: 128: e6 e10 DOI: 10.1111/ane.12082 Ó 2013 John Wiley & Sons A/S ACTA NEUROLOGICA SCANDINAVICA Clinical Commentary Switching from natalizumab to fingolimod: an observational study
More informationKeywords Multiple sclerosis. Fingolimod. Real-world evidence. Benefit risk profile. Observational study ORIGINAL ARTICLE
Neurotherapeutics (2018) 15:190 199 https://doi.org/10.1007/s13311-017-0595-y ORIGINAL ARTICLE Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the
More informationEfficacy convenience of MS treatments. Xavier Montalban Department of Neurology-Neuroimmunology. ECF Baveno 2013
Efficacy convenience of MS treatments Xavier Montalban Department of Neurology-Neuroimmunology ECF Baveno 2013 Disclaimer Dr. Montalban has received speaking honoraria and travel expenses for scientific
More informationCurrent Enrolling Clinical Trials
ASSESS RRMS patients with active disease who are still able to walk. Mariko Kita MD Description of Study/Trial: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety
More informationLife Long Brain Health and DMT Comparative Effectiveness
Life Long Brain Health and DMT Comparative Effectiveness Timothy Vollmer, MD Professor of Neurology University of Colorado Denver Medical Director- RMMSC and Co-Director Rocky Mountain MS Center at CU
More informationThe invisible facets of MS and everyday challenges clinician s perspective. Mar Tintore
The invisible facets of MS and everyday challenges clinician s perspective Mar Tintore Centre d Esclerosi Múltiple de Catalunya (Cemcat). Department of Neurology/Neuroimmunology Hospital Universitari Vall
More informationMS Academia: Multiple sclerosis advanced course
6 October 2015 - Barcelona, Spain MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Mark S. Freedman University of Ottawa and the Ottawa
More informationjournal of medicine FOR REVIEW ONLY - DO NOT DISTRIBUTE The new england february 4, 2010 Reprinted From 386 this week in the journal
Reprinted From The new england journal of medicine established in 1812 386 this week in the journal perspective 377 Medicare and Medical Technology The Growing Demand for Relevant Outcomes P.J. Neumann
More informationAbstract Background: Methods: Results: Conclusion:
1055 Two-Year Safety of, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Psoriasis: Results From a Phase 3, Randomized, Controlled Trial () Kim A. Papp, MD 1 ; Kristian Reich,
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationTriptans: Nonresponse, Recurrence, and Serious AEs for Many Patients
Efficacy, Safety, and Tolerability of Rimegepant 75 mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial,
More informationG. Anderson D. Meyer C. E. Herrman C. Sheppard R. Murray E. J. Fox J. Mathena J. Conner P. O. Buck
J Neurol (2010) 257:1917 1923 DOI 10.1007/s00415-010-5779-x ORIGINAL COMMUNICATION Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label,
More informationA comparative study of CSF neurofilament light and heavy chain protein in MS
482374MSJ1.1177/1352458513482374Multiple Sclerosis JournalKuhle et al. 213 Research Paper MULTIPLE SCLEROSIS JOURNAL MSJ A comparative study of CSF neurofilament light and heavy chain protein in MS Multiple
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More information290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3
290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3 Presentation Number: 290O Lecture Time: 11:18-11:33 Speakers: Peter
More informationConsortium of Multiple Sclerosis Centers 2015 Abstract #3485
Alemtuzumab (ALE) Improves Disability After Switch from Other Disease Modifying Therapies in a High Disability, Treatment Refractory Relapsing MS Cohort Consortium of Multiple Sclerosis Centers 2015 Abstract
More informationIndustry Relationships and Institutional Affiliations
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher
More informationProgress in the field
Progress in the field Eva Havrdová Charles University in Prague 1st Medical Faculty and General University Hospital Disclosures Dr. Havrdová has received consulting fees from Actelion, Biogen Idec, Merck,
More informationUniversity of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
More informationRandomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study
Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study Michael J Koren 1, Robert P Giugliano 2, Frederick Raal 3, David
More informationHot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018
Hot Topics Multiple Sclerosis Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018 Disclosures Natalie Parks has received compensation from Biogen, EMD Serono, Roche, and Sanofi
More informationEfficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: CZOL446H2409 Previous Study Return to List Next Study Efficacy Study of Zoledronic Acid and Combination Therapy in Women With
More informationOral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
The new england journal of medicine original article Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis Jeffrey A. Cohen, M.D., Frederik Barkhof, M.D., Giancarlo Comi, M.D., Hans-Peter
More informationAdvances in the Management of Multiple Sclerosis: A closer look at novel therapies. Disclosures
Advances in the Management of Multiple Sclerosis: A closer look at novel therapies Lily Jung Henson, MD, MMM, FAAN Chief of Neurology Piedmont Healthcare, Atlanta, GA National Association of Managed Care
More informationPresented at the Annual Congress of ECTRIMS, October 11, 2018, Berlin, Germany
Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mab), in Patients with Relapsing Forms of Multiple Sclerosis
More informationThe emergence of a new generation of multiple sclerosis
n reports n Emerging Oral Agents for Multiple Sclerosis Edward J. Fox, MD, PhD The emergence of a new generation of multiple sclerosis (MS) agents is likely to cause a significant shift in the MS treatment
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A
More informationEffect of alirocumab on the frequency of lipoprotein apheresis: A randomised Phase III trial
Effect of alirocumab on the frequency of lipoprotein apheresis: A randomised Phase III trial Patrick M. Moriarty, Klaus G. Parhofer, Stephan P. Babirak, Marc-Andre Cornier, P. Barton Duell, Bernd Hohenstein,
More informationWorkshop II. How to manage highly active MS patients in practice?
Workshop II How to manage highly active MS patients in practice? Gavin Giovannoni Department of Neurology Institute of Cell and Molecular Science Queen Mary University London & Barts and The London NHS
More informationMultiple Sclerosis: Emerging Therapies
Multiple Sclerosis: Emerging Therapies Bruce Cree, MD, PhD, MCR Conflicts of Interest EMD Serono: Grant support ovartis: Adviser, Clinical Trial Participant What are the Future Considerations for MS Therapies?
More informationWhat is Multiple Sclerosis? Gener al information
What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal
More informationSetting the Scene: Neuromyelitis Optica epidemiology, population variability, subgroups: relapsing/monophasic, Ab +ve/-ve, NMO/SD, treated/untreated
UK Nationally Commissioned NMO team Setting the Scene: Neuromyelitis Optica epidemiology, population variability, subgroups: relapsing/monophasic, Ab +ve/-ve, NMO/SD, treated/untreated Jackie Palace Disclosures
More informationA comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo
Original Research Paper A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo Patrick Vermersch, Ernst-Wilhelm Radue, Norman Putzki, Shannon Ritter, Martin
More informationStudy No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study
Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory
More informationLe Hua, MD. Disclosures Teaching and Speaking: Teva Neurosciences, Genzyme, Novartis Advisory Board: Genzyme, EMD Serono
Le Hua, MD Le Hua, MD, is a staff neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, NV. She is involved in clinical trials assessing new therapies for the treatment of MS and
More informationBruce Cree, MD, PhD, MCR. BG-12 Has Shown Nrf2 Pathway. Activation. DEFINE (BG-12/Dimethyl Fumarate) : Study Design
MS Therapies Update 212 Bruce Cree, MD, PhD, MCR BG12 Alemtuzumab Daclizumab BAF312 Erythropoetin Outline Fingolimod IFN β-1a Natalizumab Oral solumedrol Duloxetine O BG-12 Has Shown Nrf2 Pathway O OH
More informationORIGINAL ARTICLE EUROPEAN JOURNAL OF NEUROLOGY. Introduction
ORIGINAL ARTICLE Natalizumab improves ambulation in relapsing remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM N. Voloshyna a, E. Havrdova b,
More informationCharité - University Hospital, Free University and Humboldt University of Berlin, Berlin, Germany; 2 Sanofi Genzyme, Bridgewater, NJ, USA; 3
Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-blind, Monotherapy Study in Patients With Active Rheumatoid Arthritis With Intolerance or Inadequate Response to Methotrexate
More informationCSF Axonal Injury Markers
CSF Axonal Injury Markers Gavin Giovannoni Barts and The London Disclosures Professor Giovannoni has received personal compensation for participating on Advisory Boards in relation to clinical trial design,
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationWhen choosing among treatments for
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate J. Theodore Phillips, MD, PhD; Krzysztof Selmaj, MD, PhD;
More informationSimilar risk of malignancy with insulin glargine and neutral protamine Hagedorn
Letter Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, openlabel study J. Rosenstock 1,2,
More informationMULTIPLE SCLEROSIS JOURNAL Formerly Multiple Sclerosis
ISSN 1352-4585 http://msj.sagepub.com MULTIPLE SCLEROSIS JOURNAL Formerly Multiple Sclerosis Reprinted from Volume 18 Number 9 2012 Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing
More informationNeurology and Neurometabolic Unit Department of Neurological and Behavioral Sciences University of Siena Siena, Italy
Nicola De Stefano Neurology and Neurometabolic Unit Department of Neurological and Behavioral Sciences University of Siena Siena, Italy Declared receipt of honoraria or consultation fees from Novartis,
More informationClinical Drug Development. Lund , Tomas Leandersson
Clinical Drug Development Lund 2013-11-21, Tomas Leandersson Who am I? 1976: Started Medical School, Umeå University 1979: Leave of absence 1982: Ph.D. Experimental Pathology 1983-86: Member, Basel Institute
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMRI in Leber s hereditary optic neuropathy: the relationship to multiple sclerosis
RESEARCH PAPER MRI in Leber s hereditary optic neuropathy: the relationship to multiple sclerosis Multiple sclerosis Lucy Matthews, 1,2 Christian Enzinger, 3,4 Franz Fazekas, 3 Alex Rovira, 5 Olga Ciccarelli,
More informationEfficacy and Safety of Fingolimod in an Unselected Patient Population
RESEARCH ARTICLE Efficacy and Safety of Fingolimod in an Unselected Patient Population Maria Rasenack 1,2, Jonathan Rychen 1, Michaela Andelova 1,3, Yvonne Naegelin 1, Christoph Stippich 3, Ludwig Kappos
More informationClinical and research application of MRI in diagnosis and monitoring of multiple sclerosis
24-25 February 2016 - Siena, Italy Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org What
More informationTRANSPARENCY COMMITTEE Opinion 05 March 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 05 March 2014 AUBAGIO 14 mg, film-coated tablet B/28 tablets (CIP: 3400927499890) Applicant: GENZYME SAS INN ATC code
More informationTHC:CBD Daily Practice Evidence in MS Spasticity Management: The Moment of Large Databases
THC:CBD Daily Practice Evidence in MS Spasticity Management: The Moment of Large Databases Almirall-Sponsored Satellite Symposium of the 31 st Congress of the European Committee for Treatment and Research
More informationSupplemental Appendix. 1. Protocol Definition of Sustained Virologic Response. A patient has a sustained virologic response if:
Supplemental Appendix 1. Protocol Definition of Sustained Virologic Response A patient has a sustained virologic response if: 1. The patient is a responder at the end of treatment and all subsequent planned
More informationClinical Study Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study
Multiple Sclerosis International Volume 2013, Article ID 470476, 8 pages http://dx.doi.org/10.1155/2013/470476 Clinical Study Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study
More informationStudy No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary-
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information1996 vs 2013 MS Phenotype Descriptions of Progressive Disease
Learning Objectives Upon completion, participants should be able to: Describe methods of distinguishing among RRMS, SPMS, and PPMS Incorporate available evidence about emerging and recently approved novel
More informationRESEARCH/CLINICAL UPDATE
RESEARCH/CLINICAL UPDATE National Multiple Sclerosis Society 733 Third Avenue New York, New York 10017-3288 Tel +1 212.986.3240 Fax +1 212.986.7981 E-mail nat@nmss.org nationalmssociety.org May 11, 2007
More informationTop 10 Research Findings of 2016
Top 10 Research Findings of 2016 NMSS Regional Summit 2017 June 10, 2017 Rebecca Spain, MD, MSPH VA Portland Health Care System Oregon Health & Science University Disclosures Research support: NMSS Department
More informationThe ACCELERATE Trial
The ACCELERATE Trial Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Outcome Stephen J Nicholls for the ACCELERATE investigators Disclosure Research support: AstraZeneca,
More informationActivity presentations are considered intellectual property.
Activity presentations are considered intellectual property. Activity presentations are considered intellectual property and are for viewing purposes only. No content should be copied or reproduced in
More informationJEADV SHORT REPORT. Abstract
DOI: 1.1111/jdv.14738 JEADV SHORT REPORT Safety and efficacy of through 14 weeks in patients with moderate to severe psoriasis who continued on or switched from etanercept treatment: findings from the
More informationPodcast/MP3 Instructions 1. Download the Podcast or MP3 audio file to your player. 2. Listen to the presentation. 3. To receive continuing education
Podcast/MP3 Instructions 1. Download the Podcast or MP3 audio file to your player. 2. Listen to the presentation. 3. To receive continuing education credit, use the link to the online test or print the
More informationEuropean Commission Grants Approval for Mavenclad (Cladribine Tablets)
Your Contact Friederike Segeberg +49 6151 72-6328 Investor Relations +49 6151 72-3321 August 25, 2017 European Commission Grants Approval for Mavenclad (Cladribine Tablets) First oral short-course treatment
More informationDisclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
More informationIs it time to target no evident disease activity (NEDA) in multiple sclerosis?
Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Giovannoni, G; Turner, B; Gnanapavan, S; Offiah, C; Schmierer, K; Marta, M Licensed with a Creative Commons Attribution Non-Commercial
More informationNAME CTS AFFILIATION DISCLOSURE UPDATED
NAME CTS AFFILIATION DISCLOSURE UPDATED Darcy Marciniuk (Chair) and Canadian and Canadian COPD Alliance Consultant Fee, Speaker s Bureau, Advisory Committee: AstraZeneca, Boehringer-Ingelheim, Canadian
More informationDisease-modifying therapies
Updated May 2018. Please check nationalmssociety.org/dmt for the most current version of this publication. For some people, a diagnosis of multiple sclerosis (MS) is a relief, giving a name and a reason
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationClinician s view of Benefit-Risk
Clinician s view of Benefit-Risk Gordon Francis, MD Novartis, Clinical Development Clinician s View of Benefit-Risk: a need for reliable metrics A tale of 3 drugs Natalizumab MS Crohn s Disease Fingolimod
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPositive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine
Media Release Basel 21 December 2016 Positive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational
More informationAnne M. Calkins, 1 Joseph Shurman, 2 Mark Jaros, 3 Richard Kim, 4 Gwendoline Shang 4. New York Spine and Wellness Center, North Syracuse, NY; 2
Peripheral Edema and Weight Gain in Adult Patients With Painful Diabetic Peripheral Neuropathy Receiving Gabapentin Enacarbil or Pregabalin Enrolled in a Randomized, Phase 2 Trial Anne M. Calkins, 1 Joseph
More informationTh1/Th17 Cytokine Dysregulation during Different Stages of Multiple Sclerosis
Th1/Th17 Cytokine Dysregulation during Different Stages of Multiple Sclerosis Benjamin M. Segal, M.D. Holtom-Garrett Professor of Neurology Director, Multiple Sclerosis Program University of Michigan Disclosures
More informationUpdate in Multiple Sclerosis
Update in Multiple Sclerosis Kyle Smoot, MD Providence MS Center Portland, OR 1 Disclosures Research funds from Biogen. Consulting fees from Acorda, Biogen, EMDSerono, Genzyme, Novartis, and Teva. 2 Outline
More informationData on Investigational Cladribine Tablets and Rebif (interferon beta-1a) in Relapsing Forms of Multiple Sclerosis (MS) to be Presented at EAN 2018
Your Contact Erin-Marie Beals +1 781-681-2850 June 14, 2018 Data on Investigational Cladribine Tablets and Rebif (interferon beta-1a) in Relapsing Forms of Multiple Sclerosis (MS) to be Presented at EAN
More informationBiothérapies et risques infectieux en. neurologie
Biothérapies et risques infectieux en Lieu 14 Date neurologie Patrick Vermersch CHU de Lille XXIIe Journée Régionale de Pathologie Infectieuse Lille, 13 octobre 2015 Liens d intérêts Honoraires, Congrés,
More informationCase Report PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
Case Reports in Neurological Medicine, Article ID 307872, 4 pages http://dx.doi.org/10.1155/2014/307872 Case Report PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation J. Killestein,
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationDISEASE-MODIFYING THERAPIES FOR MS
DISEASE-MODIFYING THERAPIES FOR MS Updated December 2018. Please check nationalmssociety.org/dmt for the most current version of this publication. A multiple sclerosis (MS) diagnosis can bring a sense
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Use of MRI in Clinical Decision- Making
More informationClinical Study Report Assessment of Safety
Clinical Study Report Assessment of Safety Study title: Switch to RItuXimab in MS: A phase 2 open label study of Rituximab in MS patients previously treated with selfinjectibles using a target based therapy
More informationTony Traboulsee, MD Associate Professor (Medicine/Neurology) Head, UBC MS and NMO Programs. MRI Diagnostic Red Flags
Tony Traboulsee, MD Associate Professor (Medicine/Neurology) Head, UBC MS and NMO Programs MRI Diagnostic Red Flags UBC MS and NMO Research Programs LEARNING OBJECTIVES By the end of this presentation,
More informationOptimizing Immunomodulatory Therapy with Interferon Beta in Patients with Multiple Sclerosis A Prospective Study
Optimizing Immunomodulatory Therapy with Interferon Beta in Patients with Multiple Sclerosis A Prospective Study Said Masri, MD; Andreas Blodau, MD; Norbert Zessack, PhD; Michael Lang, MD; for the High
More informationSponsor Novartis. Generic Drug Name. Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title
Sponsor Novartis Generic Drug Name Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title A randomized, double-blind, multi-center, active-controlled, parallel
More informationStroke and Headache Headache and Stroke
Stroke and Headache Headache and Stroke Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Tobias Kurth Institute of Public Health Charité Universitätsmedizin Berlin
More informationCritical Pathways in Breast Cancer Treatment
Critical Pathways in Breast Cancer Treatment Faculty Jenny C Chang, MD Paul E Goss, MD, PhD Kathy D Miller, MD Lawrence N Shulman, MD Dennis J Slamon, MD, PhD Andrew Tutt, MB ChB, PhD Editor Neil Love,
More informationSYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
More information